Checkpoint Surgical Completes $16 Million Equity Financing

Woden client Checkpoint Surgical, a medical devices company, has completed a $16 million equity financing.The brand, which manufactures nerve protection and repair technology, raised the capital with investments from River Cities Capital, a growth equity firm that specializes in healthcare, Mutual Capital Partners, and several other investors. The money will be used to expand the brand’s sales force, launch new products, and increase research and development efforts.

“We witnessed firsthand Checkpoint’s impressive growth and development of a leadership position in the peripheral nerve care space,” said Wayne Wallace, Managing Director of Mutual Capital Partners. “We look forward to our continued partnership with Checkpoint.”In its engagement with the brand, Woden defined Checkpoint Surgical’s moral purpose: that patients deserve surgical outcomes that preserve and restore optimal nerve function. By aligning all aspects of the brand—from internal culture to customer experience, growth, and future strategies—behind that purpose, Checkpoint was able to articulate the importance of its product, and the effect it can have on both surgeons’ experience and patients’ health.

Now, the brand describes itself as a provider of devices that “inform intraoperative decision making to help surgeons safely and effectively protect, assess and repair motor nerves during surgery.”Investors have seen the benefit and potential of investing in a company like Checkpoint Surgical. Now, with the increased funding, the brand can do even more to help patients.“This funding will fuel the advances in peripheral nerve care we are pursuing in collaboration with nerve care specialists through innovative research and product development,” said Checkpoint Surgical President & CEO Len Cosentino.

Woden congratulates Checkpoint Surgical on the accomplishment and is eager to see what the brand can achieve with this funding.